The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...

The active ingredient in Kisqali is ribociclib. (An active ingredient is what makes a drug work.) The drug comes as a tablet that you swallow. Keep reading to learn about the common, mild ...

Ribociclib is used to treat breast cancer. Fatigue, diarrhea, headache, back pain, nausea, vomiting, or loss of appetite may occur. Nausea and vomiting can be severe. In some cases, your doctor ...

Many drugs from different chemical classes and therapeutic areas have been shown to inhibit currents mediated via the hERG-coded ion channel, which is strongly correlated to a risk of inducing TdP.

A drug called ribociclib, currently used to treat breast cancer, could slow the progression of certain pediatric high-grade gliomas, an aggressive type of childhood brain cancer, a new study has ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...